A single dose of the 2023–2024 COVID-19 mRNA vaccine prevented significant illness and death across age groups; however, its economic value was higher for older adults and higher-risk populations, according to a recent study published in JAMA Network Open .

While ongoing prevention efforts occur, COVID continues to cause significant illness and death among adults. In 2020 and 2021, the FDA authorized two mRNA vaccines, Moderna and Pfizer-BioNTech, for emergency use to prevent severe COVID. In September 2023, these monovalent COVID vaccines for the 2023–2024 season were approved.

Around the same time, the CDC’s Advisory Committee on Immunization Practices (ACIP) reviewed recommendations for their use, with an additional review in February 2024.

This study aimed to support ACIP decisi

See Full Page